Widely used:Recently Viewed
Clear All$7.75
$-0.21
(-2.64%)
As on 13-Jun-2025 16:00EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$3,608 Mln
Revenue (TTM)
$2,830 Mln
Net Profit (TTM)
$0 Mln
ROE
-8.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
86.1
Industry P/E
28.32
EV/EBITDA
9
Div. Yield
0 %
Debt to Equity
2.1
Book Value
$-0.4
EPS
$-0
Face value
--
Shares outstanding
313,420,000
CFO
$1,849.82 Mln
EBITDA
$3,215.23 Mln
Net Profit
$-301.93 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
| -- | -- | -- | -- | -- | -- | -- |
|
BSE Sensex
| 3.7 | -1.6 | 9.6 | 5.9 | 14.3 | 19.1 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
7.8 | 3,607.9 | 2,830.2 | -13.1 | 11.5 | -- | -- | 86.1 |
| 20.8 | 4,968.1 | 459.4 | 206.8 | 25.6 | 68.3 | 24.8 | 13.3 | |
| 31.4 | 3,780.7 | 8.9 | -369.2 | -4,861.1 | -26.1 | -- | 2.8 | |
| 104.1 | 5,125.5 | 432.2 | -278.3 | -64.1 | -380.9 | -- | 96.3 | |
| 56.2 | 10,781.7 | 2,937.8 | 523.9 | 23.2 | 9.3 | 20.8 | 1.9 | |
| 39.8 | 7,553.5 | 127.4 | -668.0 | -432.9 | -- | -- | 123.7 | |
| 70.1 | 7,429.5 | 685.5 | 132.9 | 15.6 | 20.1 | 60.9 | 10.9 | |
| 13.8 | 6,858.7 | 4,427.0 | 373.0 | -0.7 | 5.8 | 18.4 | 1.1 | |
| 84.0 | 4,149.4 | 1,137.8 | 214.6 | 29.2 | 12.3 | 19.6 | 2.3 | |
| 8.9 | 10,469.2 | 14,317.0 | -3,790.1 | -23.7 | -21.4 | -- | 0.7 |
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three... segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. Read more
Co-Founder, Co-CEO, President & Director
Mr. Chirag K. Patel
Co-Founder, Co-CEO, President & Director
Mr. Chirag K. Patel
Headquarters
Bridgewater, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Amneal Pharmaceuticals Inc Class A (AMRX) stood at $ 4,441 Mln as on 31-Mar-25
The share price of Amneal Pharmaceuticals Inc Class A (AMRX) is $7.75 (NYSE) and $7.75 (NASDAQ) as of 13-Jun-2025 16:00 EDT. Amneal Pharmaceuticals Inc Class A (AMRX) has given a return of --% in the last 1 years.
Amneal Pharmaceuticals Inc Class A (AMRX) has a market capitalisation of $ 3,608 Mln as on 13-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Amneal Pharmaceuticals Inc Class A (AMRX) is 86.10 times as on 13-Jun-2025, a 1679% premium to its peers’ median range of 4.84 times.
Since, TTM earnings of Amneal Pharmaceuticals Inc Class A (AMRX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Amneal Pharmaceuticals Inc Class A (AMRX) and enter the required number of quantities and click on buy to purchase the shares of Amneal Pharmaceuticals Inc Class A (AMRX).
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
The CEO & director of Mr. Chirag K. Patel. is Amneal Pharmaceuticals Inc Class A (AMRX), and CFO & Sr. VP is Mr. Chirag K. Patel.
There is no promoter pledging in Amneal Pharmaceuticals Inc Class A (AMRX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,096
|
|
|
1,054
|
|
|
755
|
|
|
741
|
|
|
709
|
|
|
532
|
|
|
522
|
|
|
421
|
|
|
386
|
| Amneal Pharmaceuticals Inc Class A (AMRX) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
11.48
|
|
Net Margin(%)
|
-0.46
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Amneal Pharmaceuticals Inc Class A (AMRX) was $0 Mln.
